Cullinan Therapeutics, Inc.

By person

19 insiders · 213 transactions

12.0×

Nadim Ahmed holds 12.0 times base salary in stock. $8.43M of shares against $698.48K in salary for 2025.

Salary from the company's own proxy. The shares are what Nadim Ahmed last reported holding, valued at $21.57, the price Common Stock was last bought or sold at on the open market here, on 8 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

BVF PARTNERS L P/IL entity

10% owner

$21.30M (10)

—

+$21.30M

64,161

0.0997%

$1.38M

−98.5%

Lynx1 Capital Management LP entity

10% owner

$13.32M (8)

—

+$13.32M

8,963,500

13.93%

$193.34M

+26.4%

F2 Vision SCS

10% owner

—

$4.76M (7)

−$4.76M

1,255,963

1.95%

$27.09M

−56.9%

Michaelson Jennifer

Chief Scientific Officer

—

$4.71M (51) scheduled

−$4.71M

158,844

0.2468%

$3.43M

+537.2%

Jovan-Embiricos Morana

10% owner

$4.20M (2)

—

+$4.20M

312,565

0.4857%

$6.74M

—

Zawel Leigh

See Remarks

—

$3.09M (10)

−$3.09M

69,785

0.1084%

$1.51M

−53.4%

GADICKE ANSBERT

Director

$6.30M (1)

$8.85M (38)

−$2.55M

23,612,189

36.69%

$509.31M

+50.2%

Savill Corrine

Chief Business Officer

—

$2.54M (9) scheduled

−$2.54M

240,990

0.3745%

$5.20M

+24.8%

UBS Oncology Impact Fund L.P. entity

10% owner

$6.30M (1)

$7.77M (19)

−$1.47M

7,648,268

11.88%

$164.97M

—

F2 Bioscience I 2017 Ltd entity

10% owner

—

$1.30M (3)

−$1.30M

537,392

0.8350%

$11.59M

−15.9%

AHMED NADIM

President and CEO

$100.32K (1)

$794.17K (10)

−$693.85K

390,803

0.6073%

$8.43M

—

Trigilio Jeffrey

Chief Financial Officer

$47.25K (1)

$689.70K (13) scheduled

−$642.45K

133,919

0.2081%

$2.89M

—

Baeuerle Patrick

Chief Scientific Officer

—

$609.95K (2) scheduled

−$609.95K

417,434

0.6486%

$9.00M

+22.3%

Jones Jeffrey Alan

Chief Medical Officer

—

$309.61K (11)

−$309.61K

159,968

0.2486%

$3.45M

—

SUMER JACQUELYN L

Chief Legal Officer

—

$235.65K (11)

−$235.65K

130,559

0.2029%

$2.82M

+6,373%

Fenton Mary Kay

Chief Financial Officer

—

$59.90K (1)

−$59.90K

127,921

0.1988%

$2.76M

+6,293%

Hughes Owen

President and CEO

$52.50K (1)

—

+$52.50K

506,226

0.7866%

$10.92M

+0.5%

Ebeling Thomas

Director

—

186,653

0.2900%

$4.03M

+176.5%

Keane Raymond T

Chief Legal Officer

—

24,124

0.0375%

$520.35K

+1,385%

Individual transactions

Insider

Date

Role

Action

Price

Amount

Lynx1 Capital Management LP

28 Oct 2025

10% owner

Buy indirect

165,667

$8.40

$1.39M

Lynx1 Capital Management LP

17 Oct 2025

10% owner

Buy indirect

32,217

$7.84

$252.57K

Lynx1 Capital Management LP

16 Oct 2025

10% owner

Buy indirect

150,000

$8.86

$1.33M

Lynx1 Capital Management LP

15 Oct 2025

10% owner

Buy indirect

51,500

$7.94

$409.05K

Lynx1 Capital Management LP

14 Oct 2025

10% owner

Buy indirect

15,032

$7.59

$114.05K

Lynx1 Capital Management LP

10 Oct 2025

10% owner

Buy indirect

277,298

$7.36

$2.04M

Lynx1 Capital Management LP

9 Oct 2025

10% owner

Buy indirect

626,043

$6.70

$4.19M

Lynx1 Capital Management LP

8 Oct 2025

10% owner

Buy indirect

556,300

$6.46

$3.59M

AHMED NADIM

6 Jun 2022

President and CEO

Buy

8,090

$12.40

$100.32K

BVF PARTNERS L P/IL

1 Jun 2022

10% owner

Buy

44,746

$11.00

$492.18K

BVF PARTNERS L P/IL

1 Jun 2022

10% owner

Buy

301,009

$11.00

$3.31M

BVF PARTNERS L P/IL

1 Jun 2022

10% owner

Buy

405,641

$11.00

$4.46M

BVF PARTNERS L P/IL

13 May 2022

10% owner

Buy

17,744

$9.14

$162.09K

BVF PARTNERS L P/IL

13 May 2022

10% owner

Buy

38,558

$9.14

$352.23K

BVF PARTNERS L P/IL

13 May 2022

10% owner

Buy

53,598

$9.14

$489.62K

BVF PARTNERS L P/IL

12 May 2022

10% owner

Buy

457,001

$9.06

$4.14M

BVF PARTNERS L P/IL

12 May 2022

10% owner

Buy

542,999

$9.06

$4.92M

BVF PARTNERS L P/IL

1 Apr 2022

10% owner

Buy

9,402

$10.75

$101.07K

BVF PARTNERS L P/IL

1 Apr 2022

10% owner

Buy

266,598

$10.75

$2.87M

Trigilio Jeffrey

12 Jan 2021

Chief Financial Officer

Buy

2,250

$21.00

$47.25K

Hughes Owen

12 Jan 2021

President and CEO

Buy

2,500

$21.00

$52.50K

Jovan-Embiricos Morana

12 Jan 2021

Director

Buy indirect

104,762

$21.00

$2.20M

Jovan-Embiricos Morana

12 Jan 2021

Director

Buy indirect

95,238

$21.00

$2.00M

GADICKE ANSBERT

12 Jan 2021

Director

Buy indirect

300,000

$21.00

$6.30M

UBS Oncology Impact Fund L.P.

12 Jan 2021

10% owner

Buy

300,000

$21.00

$6.30M

Show all 213 transactions →

Cullinan Therapeutics, Inc.

By person

Individual transactions

What was left out